Spanish drugmaker Almirall has said it may decide to withdraw multiple sclerosis spasticity treatment Sativex from the German market after a breakdown in talks with the country's reimbursement authorities.
Sativex (nabiximols) is available in eight markets around the world - including six countries in Europe - but the pricing mandated by the German authorities undercuts the product's price elsewhere, according to its original developer GW Pharmaceuticals.
Neither Almirall nor GW Pharma has disclosed the price mandated by Germany's Federal Joint Committee (G-BA) for Sativex after months of negotiations and arbitration proceedings, although GW Pharma said it was "unacceptable" and "significantly lower than the reimbursed Sativex price in other European countries".
http://www.pharmatimes.com/Article/13-03-21/Almirall_may_pull_Sativex_in_Germany.aspx?
No comments:
Post a Comment